A new cholesterol-lowering medication developed by Novartis, named pelacarsen, has failed to deliver the anticipated results in preventing heart attacks and strokes, leaving researchers in disbelief. This experimental drug was designed to target lipoprotein(a), a genetically inherited cholesterol that contributes to artery plaque formation.
During a recent presentation at the American Heart Association conference, data revealed that participants using pelacarsen experienced no significant reductions in the incidence of strokes, heart attacks, or cardiovascular-related deaths. The study, known as the Horizon trial, involved over 8,300 individuals with elevated lipoprotein(a) levels who had previously suffered heart-related issues.
“I expected this to be a slam dunk,” expressed Dr. Amanda Doran from Vanderbilt University Medical Center, which played a key role in the trial. “We were deeply invested in this, so the outcome is particularly disheartening.”
Lipoprotein(a) is a unique form of cholesterol, distinct from low-density lipoprotein (LDL), that is solely inherited and affects about 20% of the U.S. population. Unlike LDL, lifestyle changes such as diet and exercise do not impact lipoprotein(a) levels, intensifying the urgency for effective treatments.
Despite pelacarsen successfully decreasing lipoprotein(a) levels by 78% compared to a placebo’s 13%, this drop did not translate into better cardiovascular health outcomes. Dr. Steven Nissen, who led the trial at the Cleveland Clinic, was taken aback by these findings, stating, “We all assumed that significantly lowering lipoprotein(a) would lead to fewer cardiovascular events, but this study shows otherwise.”
The Horizon trial’s results have raised questions about the role of lipoprotein(a) in cardiovascular health. While the study did not demonstrate the expected benefits of lowering this cholesterol type, Dr. John Wilkins from Northwestern Medicine emphasized that lipoprotein(a) remains a key marker for assessing heart disease risk. He noted that more research is needed to identify effective treatments that could potentially lower this risk in patients.
Looking ahead, while pelacarsen may not be pursued further, other medications targeting lipoprotein(a) are in development, including those from Eli Lilly and Amgen. As researchers continue to explore innovative solutions, the medical community remains hopeful about ultimately finding effective therapies for managing lipoprotein(a) and enhancing cardiovascular health.
Photo credit: Getty / iStockphoto
